This study demonstrates that common pharmacy claims-based measures underestimate the effect of actual adherence on inpatient costs among patients with serious mental illness.
Felicia Forma, BSc
Advertisement
Articles by Felicia Forma, BSc
Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.
Higher cost-sharing levels reduced adherence to antidiabetic medications in patients with type 2 diabetes.
Advertisement
Latest Updated Articles
- The Cost of Adherence Mismeasurement in Serious Mental Illness: A Claims-Based Analysis
Published: May 16th 2017 | Updated:
- Cost Sharing, Adherence, and Health Outcomes in Patients With Diabetes
Published: August 11th 2010 | Updated:
- Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
Published: February 12th 2013 | Updated:
- Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
Published: July 2nd 2013 | Updated:
- Improving Patient-Centered Care in Diabetes With Comparative Effectiveness Research
Published: September 30th 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
White House to Announce Second Drug Pricing Deal as AstraZeneca Joins TrumpRx
3
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
4
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
5
